In 70 chronic hepatitis B patients with hepatitis B surface antigen seroclearance during nucleos(t)ide analogue therapy, response was sustained in all 54 patients who discontinued treatment. Clinically significant relapses as indicated by high hepatitis B virus DNA and ALT levels were not observed. Anti-HBs positivity may not be required to ensure sustained off-treatment response.
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Currently, nucleos(t)ide analogues (NAs) play a major role in the treatment of chronic hepatitis B (CHB) patients. NAs effectively inhibit hepatitis B virus (HBV) replication, a key driver of disease progression [1] . However, immune control over the virus and serological responses, such as hepatitis B surface antigen (HBsAg) seroclearance, are rarely achieved due to the limited effect of NA on the covalently closed circular DNA [2] . The risk of relapse is high when NAs are stopped before HBsAg seroclearance [3, 4] . Therefore, in clinical practice NAs are generally prescribed as a long-term or even indefinite treatment.
HBsAg seroclearance is associated with a reduced risk of disease progression and is often considered as a functional cure of CHB [5] [6] [7] . HBsAg seroclearance may therefore be the ideal endpoint for successful NA discontinuation. This is also suggested by the latest CHB management guidelines, in which continued treatment until HBsAg seroclearance is increasingly recommended [8, 9] . Yet, there are very few clinical studies that provide evidence regarding the durability of response after NA-induced HBsAg seroclearance due to the rarity of this endpoint. A recent study reported good sustained off-treatment response and event-free survival after NA stop, but only Asian patients were investigated [10] . In addition, the effect of anti-HBs positivity at time of NA discontinuation or consolidation therapy beyond HBsAg seroclearance on sustained offtreatment response remains unknown.
The aim of this real-life cohort study of Caucasian and Asian CHB patients was to investigate the sustainability of response after HBsAg seroclearance during NA therapy and subsequent treatment cessation. In addition, we investigated the effect of anti-HBs positivity and consolidation therapy beyond HBsAg seroclearance on sustained response.
METHODS

Patients
This was an international, multicenter, observational study of CHB patients who received NA treatment for at least 1 year with on-treatment HBsAg seroclearance between 1997 and 2015. Exclusion criteria were interferon therapy during NA treatment; coinfection with human immunodeficiency virus, hepatitis C virus, or hepatitis D virus; concomitant other liver disease; liver transplantation; or liver cancer.
Approval was obtained from ethics committees of all centers. The study was performed in compliance with the Declaration of Helsinki.
Methods
Data were systematically collected according to a predefined protocol. Patients were evaluated at least every 3-6 months or more often if indicated. Cirrhosis was diagnosed based on histology or ultrasonographic signs of cirrhosis (nodules within liver parenchyma, spleen size >12 cm, or portal vein >16 mm) [11] .
Biochemical and serological tests were performed with local well-validated, standardized automated techniques and commercially available immunoassays. Alanine aminotransferase (ALT) levels were standardized according to gender and the local upper limit of normal (ULN). Sensitive real-time polymerase chain reaction assays were used to measure HBV DNA levels. Undetectable HBV DNA was defined as HBV DNA <20 IU/mL. A serum anti-HBs level >10 IU/mL was considered as positive.
Study endpoints included anti-HBs seroconversion, detectable HBV DNA (>20 IU/mL), HBsAg seroreversion, virological relapse (HBV DNA >2000 IU/mL), and ALT elevation >2× ULN.
Data Analyses
In order to assess endpoints after treatment discontinuation, off-treatment follow-up time was calculated from NA stop (time = 0) until an endpoint or last follow-up visit. For antiHBs seroconversion, the time of HBsAg seroclearance was considered as time = 0. Kaplan-Meier analysis and the log-rank test were used to analyze time-to-event endpoints.
Statistical tests were 2-sided with a P value < .05 considered as statistically significant. All tests were performed using SPSS, version 21.0 (IBM Corp., Armonk, New York).
RESULTS
Study Population
In a cohort of 5872 CHB patients treated with NA therapy, 70 who cleared serum HBsAg were identified. Of these 70 patients, 46% were Caucasian and 44% were Asian (Supplementary Table  1 ). At start of treatment, 31 patients (44%) were HBeAg positive and 39 (56%) were HBeAg negative. The median time from NA initiation until HBsAg seroclearance was shorter in pretreatment HBeAg-positive patients compared to pretreatment HBeAg-negative patients (3.6 vs 5.1 years; P = .011). After HBsAg seroclearance, anti-HBs seroconversion developed in 51 of the 70 patients, resulting in cumulative rates of 63%, 82%, and 91% at year 1, 3, and 5, respectively (Supplementary Figure 1) .
Durability of Response After Hepatitis B Surface Antigen Seroclearance
Of the 70 patients, 16 were still on NA at last follow-up visit. Overall, the 70 patients contributed to 760 person-months between HBsAg seroclearance and the last on-treatment visit. During these 760 months, no HBV DNA elevations or HBsAg reversions were observed.
NA was discontinued in 54 (77%) patients, with all patients being negative for HBV DNA, HBeAg, and HBsAg at treatment discontinuation (Supplementary Table 1 ). Cirrhosis (compensated) was present in 8 of the 54 patients (15%). Treatment was continued for a median of 7 months (interquartile range [IQR], 6-14) beyond HBsAg seroclearance. At least 2 consecutive confirmations of HBsAg negativity were made before treatment discontinuation in 52 of the 54 patients (96%). At NA cessation, 30 (56%) patients were anti-HBs positive with a median duration of anti-HBs positivity of 5 months (IQR, 0-10).
During a median off-treatment follow-up of 1.6 years (IQR, 0.5-2.7), 5 of the 54 patients developed detectable HBV DNA (range, 23-1320 IU/mL) while remaining HBsAg negative (Table 1) . Of these 5 patients, 1 had cirrhosis and was retreated immediately. In addition, 2 of the 54 patients developed HBsAg reversion while maintaining undetectable HBV DNA (Table 1) . Of these 2 patients, 1 was HBsAg positive until the end of follow-up, while the other became HBsAg negative again. The cumulative rates of the composite development of detectable HBV DNA or HBsAg reversion were 10% and 16% at year 1 and year 5, respectively (Supplementary Figure 2) . None of the patients developed a full virological relapse as indicated by combined HBsAg reversion and high HBV DNA levels.
No patients developed ALT levels >2× the ULN. None of the patients developed hepatic decompensation or hepatocellular carcinoma (HCC), and no patients died.
DISCUSSION
In this multiethnic cohort of Caucasian and Asian CHB patients with HBsAg seroclearance during NA therapy, we demonstrated that the response was durable in most patients regardless of anti-HBs positivity, even after subsequent NA discontinuation. None of the patients developed a clinically significant relapse with high HBV DNA and ALT levels. A minority of patients developed detectable HBV DNA or HBsAg reversion, which were mostly mild and transient, and never in combination with each other. Studies are scarce regarding the durability of response after HBsAg seroclearance during NA therapy and were mostly performed in Asian patients. Our study included a significant number of Caucasian patients (46%), demonstrating good durability of response after HBsAg seroclearance and subsequent NA stop. Detectable HBV DNA and HBsAg reversion were observed, but these episodes were transient and did not lead to any ALT flares. These episodes did not result in true disease reactivation as is frequently seen in HBsAg-positive patients who have discontinued NA treatment [3, 4] . In line with our results, a study of Korean patients showed that none of the patients developed HBV DNA levels >2000 IU/mL when NA was stopped after HBsAg seroclearance [10] .
Although HBsAg seroclearance appears to be a safe endpoint for NA therapy discontinuation according to the guidelines [8, 9] , there is limited evidence regarding the importance of anti-HBs positivity or consolidation therapy beyond HBsAg seroclearance. It is important to note that in our study, 44% of the patients were anti-HBs negative when NA was stopped. The absence of relapses in this group after NA cessation suggests that HBsAg negativity by itself indeed likely reflects disease remission and/ or immune control and may be sufficient to stop NA [5, 12] . Likewise, a low level of HBsAg at the end of treatment has been demonstrated as a strong, independent predictor of sustained response in HBsAg-positive patients who discontinued NA therapy [13] .
It remains controversial whether it is safe for patients with cirrhosis to stop NA due to their increased risk of hepatic decompensation and HCC [3, 4] . In our study, high off-treatment HBV DNA levels or ALT flares were not observed. In contrast, in a Chinese study of 22 patients who stopped NA after HBsAg loss, 1 patient developed HBV DNA elevation >5 log IU/mL and ALT >500 U/L [14] . Therefore, the risk of hepatic decompensation may be present in patients with cirrhosis. Furthermore, studies have demonstrated that HCCs do occur after HBsAg seroclearance mainly in those with cirrhosis [7, 10, 15] . Considering the risk of these adverse outcomes, HCC surveillance and confirmation of sustained off-treatment response should be continued in cirrhotic patients who cleared serum HBsAg.
Our study is limited by its retrospective design. However, due to the rarity of NA-induced HBsAg seroclearance, it may be difficult to study this in a prospective manner. Long-term follow-up studies with larger numbers of patients are warranted to assess the incidence and risk factors of adverse clinical outcomes after NA-induced HBsAg seroclearance.
In conclusion, in this real-life, multiethnic cohort of CHB patients treated with NA, HBsAg seroclearance was a safe endpoint for treatment discontinuation with subsequent sustained off-treatment response. Clinically significant relapses, as indicated by high HBV DNA and ALT levels, were not observed. Anti-HBs positivity may not be required to ensure sustained off-treatment response. Future studies are warranted regarding HCC development after NA-induced HBsAg seroclearance in order to identify high-risk patients.
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